FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares

TUESDAY, Sept. 6, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
SPEVIGO is a novel, selective antibody infusion that blocks the activation of the interleukin-36 receptor, which is part of an immune system signaling pathway thought to be involved in the cause of GPP. The approval was based on a 12-week trial in which 53 patients with a GPP flare were treated with SPEVIGO or placebo. After one week, more patients treated with SPEVIGO showed no visible pustules than those treated with placebo (54 versus 6 percent).
The most common adverse reactions (≥5 percent) reported in patients taking SPEVIGO were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection.
“GPP flares can greatly impact a patient’s life and lead to serious, life-threatening complications,” Mark Lebwohl, M.D., lead investigator for the trial, said in a statement. “The approval of SPEVIGO is a turning point for dermatologists and clinicians.”
Approval of SPEVIGO was granted to Boehringer Ingelheim.
Was this page helpful?
Related Posts
Genicular Nerve Radiofrequency Ablation Reduces Knee Arthritis Pain
FRIDAY, March 3, 2023 (HealthDay News) -- Genicular nerve radiofrequency...
Una forma de tratamiento para la infertilidad podría aumentar el riesgo de cáncer a largo plazo en los hijos
JUEVES, 1 de septiembre de 2022 (HealthDay News) -- Los niños que nacen como...
AI-Enabled Retinal Vasculometry May Help Assess Vascular Health
WEDNESDAY, Oct. 5, 2022 (HealthDay News) -- Artificial intelligence (AI)-enabled...
El racismo durante la juventud deja a las mujeres negras con un riesgo duradero de depresión
LUNES, 28 de febrero de 2022 (HealthDay News) -- Las mujeres negras que...